为了有效开展丹酚酸类成分的药物发现研究工作，课题组前期在阐明丹酚酸类成分体内外构效关系的基础上，提出抗氧化基团与(+)-苯基乳酸的有机融合是丹酚酸类成分活性保证的前提，并以此为药物设计理念，结合临床上的抗氧化药物，设计、合成了PDs和EDs两个系列化合物，然后经分子、细胞及整体动物模型评价，最终发现了脂溶性和相关药理活性如抗氧化、抗血栓等作用显著改善、且有降低出血风险研究前景的EDs类化合物。接下来，本课题拟以EDs化合物为先导物，全面深入的设计、合成新的EDs化合物，研究并阐明该类化合物的抗氧化、自由基清除、抑制内皮细胞凋亡构效关系及主要作用机制，再经体内抗血栓、脑缺血再灌注及生物利用度评价，以期寻找到机制明确、有效性和口服生物利用度提高的用于临床前深入研究的EDs候选物。

In order to effectively carry out the drug discovery of salvianolic acids, we firstly studied and elucidated the structure-activity relationships (in vitro and vivo) of salvianolic acids, and proposed the integration of antioxidant group and (+)-phenyl lactic acid was the activity-premise of salvianolic acids. Based on this concept, we designed and synthesized the PDS and EDS series of compounds, which were evaluated via the molecular, cellular and animal model, and found the EDs compound showed improved liposolubility, antioxidant, anti-thrombosis effects, as well as displayed a prospect studied for the reduced bleeding risk. Next, we will use the EDs compound as the precursor, and further design and synthesize new series of EDs compounds to study their structure-activities of antioxidant, radicals scavenging, inhibition of endothelial cell apoptosis in vitro, followed by evaluating their anti-thrombosis and cerebral ischemia reperfusion injuries to obtain the pro-drug candidates of EDs analogues with enhanced oral bioavailability.